INmune Bio is pairing a quantum machine with AI to find diseases beyond Alzheimer’s that its drug candidate might help.

The Florida biotech takes on a pulmonary hypertension pipeline backed by Fairmount, with cash it says should last into 2029.

A new review argues postpartum recovery may shape lifelong aging; a fandom health standard asks who helps mothers get there.

Immorta Bio says its AI-designed SenoMune-0257 prompts T cells to clear senescent cells, and plans first human evaluation ...

TimePie's Hebe Chen spotlights key developments from Shanghai, from therapeutic targets to China’s expanding clinical ...

Berlin keynote details Eos SENOLYTIX's pre-clinical results with mitochondrial-targeted geropeptide on healthspan and lifespan.

Cognition Therapeutics wins a US patent on a new crystal form of zervimesine and has an FDA meeting on its Lewy body trial ...

Niagen Bioscience’s new Niagen Plus vial comes pre-filled and needs no mixing. It is available via a telehealth platform from ...

KAUST and Oxford researchers used a transistor-based sensor to read three forms of alpha-synuclein, reaching 90.9% accuracy ...

Zealand Pharma and Generate Biomedicines will design multispecific proteins for metabolic disease, in a deal with nearly ...

As its CEO takes the stage in Berlin, the company opens a window on its longest-lived treated mice – and the data behind them ...

As pharma shops for de-risked science, venture money is moving later and concentrating in fewer, bigger bets – our report ...